DNA vaccination

Aegis Life, Inc. Appoints Hong Jiang, Ph.D., as Chief Operating Officer

Retrieved on:

Wednesday, September 9, 2020

Biotechnology, Infectious diseases, Hospitals, Health, Pharmaceutical, Vaccination, Virology, Articles, Business, Branches of biology, Vaccine, DNA vaccination, Chief operating officer

Aegis Life, Inc. , the leading developer of the next generation of DNA vaccines and therapies for the worlds most dangerous diseases, announced today that it has appointed its co-founder, Hong Jiang, Ph.D., as its Chief Operating Officer (COO).

Key Points:

Aegis Life, Inc. , the leading developer of the next generation of DNA vaccines and therapies for the worlds most dangerous diseases, announced today that it has appointed its co-founder, Hong Jiang, Ph.D., as its Chief Operating Officer (COO).
She also has previously co-founded three companies in the mobile and wireless space, including Roundbox, Tatara Systems and Flarion Technologies.
As COO of Aegis Life, Dr. Jiang will be responsible overseeing its business operations, including raising capital, business development and manufacturing scale-up.
At Aegis Life, we are developing the next generation of DNA vaccines and therapies for the worlds most dangerous diseases, including COVID-19.

Enesi Pharma to Develop Thermostable Solid Dose DNA Vaccine Targeting Zika Virus under New Partnership with The University of Adelaide

Retrieved on:

Thursday, September 3, 2020

Vaccination, Medical specialties, Medicine, Virology, Health, Vaccines, Vaccine, RTT, Zika virus, DNA vaccination, Zika fever, RNA vaccine

This project aims to employ Enesi's ImplaVax formulation expertise and platform to create a protective Zika virus DNA vaccine in a solid dose implant format for transcutaneous delivery via a needle-free device.

Key Points:

This project aims to employ Enesi's ImplaVax formulation expertise and platform to create a protective Zika virus DNA vaccine in a solid dose implant format for transcutaneous delivery via a needle-free device.
DNA and RNA vaccines are becoming increasingly prominent and hold great potential against many diseases, as highlighted by the ongoing Covid-19 crisis.
The new AUD1.35 million collaboration with the University of Adelaide aims to advance the development of a novel thermostable, solid dose Zika virus DNA vaccine to Phase 1 clinical trials.
We are particularly excited that this new collaboration is focused on advancing the development of a solid dose DNA vaccine through application of our ImplaVax technology.

Enesi Pharma to Develop Thermostable Solid Dose DNA Vaccine Targeting Zika Virus under New Partnership with The University of Adelaide

Retrieved on:

Thursday, September 3, 2020

Vaccination, Medical specialties, Medicine, Virology, Health, Vaccines, Vaccine, RTT, Zika virus, DNA vaccination, Zika fever, RNA vaccine

This project aims to employ Enesi's ImplaVax formulation expertise and platform to create a protective Zika virus DNA vaccine in a solid dose implant format for transcutaneous delivery via a needle-free device.

Key Points:

This project aims to employ Enesi's ImplaVax formulation expertise and platform to create a protective Zika virus DNA vaccine in a solid dose implant format for transcutaneous delivery via a needle-free device.
DNA and RNA vaccines are becoming increasingly prominent and hold great potential against many diseases, as highlighted by the ongoing Covid-19 crisis.
The new AUD1.35 million collaboration with the University of Adelaide aims to advance the development of a novel thermostable, solid dose Zika virus DNA vaccine to Phase 1 clinical trials.
We are particularly excited that this new collaboration is focused on advancing the development of a solid dose DNA vaccine through application of our ImplaVax technology.

Aegis Life, Inc. Launches to Fight COVID-19 via DNA Vaccines and Therapeutics Enabled by Proprietary Fusogenix Delivery Technology

Retrieved on:

Tuesday, September 1, 2020

Infectious diseases, Biotechnology, Health, Medical devices, Branches of biology, Biology, Articles, Vaccination, Biotechnology, Gene delivery, Vaccines, COVID-19 vaccine, Medical research, Vaccine, Electroporation, DNA vaccination

Aegis Life , Inc. has been founded with a goal of developing a novel DNA vaccine that is differentiated from other SARS-CoV-2 vaccine approaches, using the Entos Pharmaceuticals breakthrough Fusogenix gene delivery technology.

Key Points:

Aegis Life , Inc. has been founded with a goal of developing a novel DNA vaccine that is differentiated from other SARS-CoV-2 vaccine approaches, using the Entos Pharmaceuticals breakthrough Fusogenix gene delivery technology.
Entos Pharmaceuticals developed the Fusogenix technology over the past decade, and has broadened Fusogenix adoption through multiple spinouts and partnerships.
When COVID-19 hit, we realized that the technology is ideally suited to deliver DNA vaccines and therapeutics.
Fusogenix gene delivery technology is an alternative to using electroporation devices to deliver DNA inside human cells.

Global Preventive Vaccines Market, 2020-2030

Retrieved on:

Wednesday, August 12, 2020

Vaccination, Medical specialties, Branches of biology, Medicine, Virology, Vaccines, Gene delivery, Vaccine, Viral vector, DNA vaccination, HIV vaccine, Influenza vaccine

Vaccines are versatile preventive formulations that have, so far, enabled the global eradication of smallpox (1980) and polio (2015), which are both debilitating viral diseases.

Key Points:

Vaccines are versatile preventive formulations that have, so far, enabled the global eradication of smallpox (1980) and polio (2015), which are both debilitating viral diseases.
Given the rate at which the global population is growing, the demand for vaccines is anticipated to increase significantly.
Moreover, many developers claim to be working on next generation preventive vaccine candidates, such as recombinant vaccines, viral vector-based vaccines and DNA vaccines, which have been demonstrated to elicit powerful immune responses, resulting in the development of immunologic memory.
The 'Global Preventive Vaccines Market, 2020-2030' report features an extensive study of the current market landscape and future opportunities associated with the preventive vaccine domain.

INOVIO Reports Second Quarter 2020 Financial Results; Provides DNA Medicines Clinical Program Mid-Year Update

Retrieved on:

Monday, August 10, 2020

Vaccination, Medical specialties, Inovio Pharmaceuticals, Biotechnology, Vaccine, Medicine, DNA vaccination

INOVIO's management will host a live conference call and webcast at 4:30 p.m. Eastern Time today to discuss financial results and provide a general business update, including near-term expectations for its COVID-19 DNA vaccine development program and a mid-year clinical program update for its DNA medicines portfolio.

Key Points:

INOVIO's management will host a live conference call and webcast at 4:30 p.m. Eastern Time today to discuss financial results and provide a general business update, including near-term expectations for its COVID-19 DNA vaccine development program and a mid-year clinical program update for its DNA medicines portfolio.
INOVIO reported positive interim clinical data from the first two cohorts in its Phase 1 clinical trial in the U.S.
INOVIO has received significant funding from government and private sources in 1H 2020 to support vaccine development and manufacturing scale-up.
The DoD also awarded Ology Bioservices $11.9 million to work with INOVIO to manufacture INO-4800 DNA plasmids.

Entos Pharmaceuticals Announces Selection of Lead DNA Vaccine Candidates for COVID-19 and a $4.2M Award to Move Forward with Phase I/II Human Trials

Retrieved on:

Thursday, June 25, 2020

Health, Infectious diseases, Other Science, Research, Science, Pharmaceutical, Biotechnology, Medical specialties, Medicine, Immunology, Vaccination, Branches of biology, Virology, Immunogenicity, Vaccines, DNA vaccination, Vaccine, Antibody, Severe acute respiratory syndrome-related coronavirus

In collaboration with academic and industrial partners, Entos rapidly developed a panel of recombinant plasmid DNA vaccine candidates encoding in silico-optimized and conserved regions of the SARS-CoV-2 spike protein.

Key Points:

In collaboration with academic and industrial partners, Entos rapidly developed a panel of recombinant plasmid DNA vaccine candidates encoding in silico-optimized and conserved regions of the SARS-CoV-2 spike protein.
The two lead Covigenix candidates showed robust preclinical in vivo results, achieving all vaccine profile targets, including potency, ADE safety assessment, high immunogenicity, and efficacy.
Lead Covigenix candidates stimulated neutralizing antibody levels and balanced T helper cell immunity in mouse models.
We look forward to continue working closely with our collaborators to initiate Phase I/II human clinical trials this summer.

INOVIO Receives $71 Million Contract From U.S. Department of Defense To Scale Up Manufacture of CELLECTRA® 3PSP Smart Device and Procurement of CELLECTRA® 2000 for COVID-19 DNA Vaccine

Retrieved on:

Tuesday, June 23, 2020

Viruses, Branches of biology, Biology, Zoonoses, Vaccination, Gene delivery, Coronaviridae, In Saudi Arabia, Severe acute respiratory syndrome-related coronavirus, DNA vaccination, Vaccine, Severe acute respiratory syndrome

CELLECTRA3PSP is designed to deliver INO-4800 directly into the skin, where the vaccine prompts the body's immune system to drive a robust immune response.

Key Points:

CELLECTRA3PSP is designed to deliver INO-4800 directly into the skin, where the vaccine prompts the body's immune system to drive a robust immune response.
Initial development of this next generation CELLECTRA3PSP smart device began in 2019 with$8.1 millionin funding from the medical arm of the U.S. Defense Threat Reduction Agency's Medical CBRN Defense Consortium.
INO-4800 is INOVIO's DNA vaccine candidate being developed to protect against the novel coronavirus SARS-CoV-2, which causes COVID-19.
INOVIO's DNA medicines deliver optimized plasmids directly into cells intradermally or intramuscularly using INOVIO's proprietary hand-held smart device called CELLECTRA.

Worldwide DNA Vaccine Market (2020 to 2022) - Increasing Focus on Genetic Vaccine Development

Retrieved on:

Thursday, June 18, 2020

Vaccination, Branches of biology, Biology, Life sciences, Vaccines, Biotechnology, Vaccine, Virology, Molecular biology, Recombinant DNA, DNA vaccination, Influenza vaccine

This comprehensive report entitled Global DNA Vaccine Market Outlook 2022 provides an in-depth analysis of the global DNA Vaccines market, presenting readers a profound understanding of the various challenges, drivers, and developments in this industry.

Key Points:

This comprehensive report entitled Global DNA Vaccine Market Outlook 2022 provides an in-depth analysis of the global DNA Vaccines market, presenting readers a profound understanding of the various challenges, drivers, and developments in this industry.
The report also contains a detailed and in-depth analysis of the segmentation of the DNA vaccines market based on types of DNA vaccines, therapeutic indication, end-users, and geography.
Based on the type, the DNA vaccines market is divided into recombinant protein and genetic.
The last section of the report discusses the recommendations which could help the DNA vaccine market grow at a faster pace.

Immunomic Therapeutics Enters into License Agreement with Ichor Medical Systems to Use Electroporation (EP) Delivery Technology in Phase I Study of DNA Vaccine Therapy, ITI-1001

Retrieved on:

Tuesday, June 16, 2020

ITI will leverage Ichors TriGrid Electroporation technology to increase cellular uptake of ITI-1001 when administered to patients with newly diagnosed Glioblastoma, or GBM.

Key Points:

ITI will leverage Ichors TriGrid Electroporation technology to increase cellular uptake of ITI-1001 when administered to patients with newly diagnosed Glioblastoma, or GBM.
DNA vaccines delivered by conventional injection have experienced challenges to delivery efficiency, resulting in suboptimal immune responses in clinical trials.
We are pleased to collaborate with a recognized leader in the delivery of nucleic acid-based medicines and we look forward to initiating patient dosing in 2021.
Ichor Medical Systems clinical stage TriGrid Delivery System is the first integrated and fully automated device for electroporation-mediated nucleic acid administration in humans.